MedTrace Logo

Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

NCT00350025 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2017-03-31

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.

Conditions

  • Urologic Neoplasm

Interventions

DRUG

Cetuximab

Cetuximab 250mg/m2 IV weekly for each 28 day cycle.

DRUG

Paclitaxel

Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.

Sponsors & Collaborators

Principal Investigators

  • Yu-Ning Wong, MD · Fox Chase Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2010-07-31
Completion
2012-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00350025 on ClinicalTrials.gov